The United Kingdom and the United States have reached a landmark bilateral deal that will keep zero levies on UK pharmaceutical products entering the American market.
The Terms of the Accord
As part of the deal, the UK has committed to raise spending on drugs through the public health system. This commitment ensures that import taxes on these crucial goods will be held at nothing for a duration of 36 months.
This agreement is in response to earlier statements to dramatically increase import taxes on patented drug imports, with increases mentioned reaching 100%.
"This deal with the United Kingdom reinforces the international landscape for innovative medicines and introduces long-overdue fairness to U.S.–U.K. drug exports," a statement noted.
Economic Significance
Pharmaceuticals constitute one of the UK's biggest export categories to the United States, which is by far the biggest buyer for large British pharmaceutical firms.
Trade data show that in the year leading up to the third quarter, the UK shipped medicines totaling £11.1bn to the US. This amount made up nearly one-fifth of total UK exports in that period.
"This deal protects employment, boosts funding and facilitates the UK to establish itself as a worldwide center for life sciences," a minister remarked.
Key UK Commitments
The deal involves several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new therapies to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a aim to raise overall public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The sum drug companies must refund to the NHS to stay within budget will be limited at 15%. Previously, rebates were more than twenty percent.
Industry Background
This agreement comes amid a ongoing dispute between the sector and the UK government over medicine costs and approval rates.
These tensions were exacerbated by arguments that US patients were charged several times more for the same drugs than people in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been paused or cancelled, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS must spend more on medicines, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the past decade.
